CHE Quote, Financials, Valuation and Earnings

Amedisys has a net margin of 14.11% compared to Chemed's net margin of -3.41%. Chemed's return on equity of 25.8% beat Amedisys's return on equity of 3.71%.

Chemed has a consensus price target of $675.00, signalling upside risk potential of 13.75%. On the other hand Amedisys has an analysts' consensus of $96.86 which suggests that it could grow by 5.84%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

Chemed has a beta of 0.494, which suggesting that the stock is 50.626% less volatile than S&P 500. In comparison Amedisys has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.035%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.32%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $640M, which are larger than Amedisys quarterly revenues of $598.1M. Chemed's net income of $90.3M is higher than Amedisys's net income of -$20.4M. Notably, Chemed's price-to-earnings ratio is 29.80x while Amedisys's PE ratio is 69.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.71x versus 1.29x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst has a net margin of 14.11% compared to Chemed's net margin of -25.97%. Chemed's return on equity of 25.8% beat Health Catalyst's return on equity of -19.29%.

Chemed has a consensus price target of $675.00, signalling upside risk potential of 13.75%. On the other hand Health Catalyst has an analysts' consensus of $8.45 which suggests that it could grow by 115.13%. Given that Health Catalyst has higher upside potential than Chemed, analysts believe Health Catalyst is more attractive than Chemed.

Chemed has a beta of 0.494, which suggesting that the stock is 50.626% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.435, suggesting its more volatile than the S&P 500 by 43.508%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.32%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $640M, which are larger than Health Catalyst quarterly revenues of $79.6M. Chemed's net income of $90.3M is higher than Health Catalyst's net income of -$20.7M. Notably, Chemed's price-to-earnings ratio is 29.80x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.71x versus 0.77x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 14.11% compared to Chemed's net margin of 4.47%. Chemed's return on equity of 25.8% beat Option Care Health's return on equity of 14.93%.

Chemed has a consensus price target of $675.00, signalling upside risk potential of 13.75%. On the other hand Option Care Health has an analysts' consensus of $38.44 which suggests that it could grow by 21.85%. Given that Option Care Health has higher upside potential than Chemed, analysts believe Option Care Health is more attractive than Chemed.

Chemed has a beta of 0.494, which suggesting that the stock is 50.626% less volatile than S&P 500. In comparison Option Care Health has a beta of 1.074, suggesting its more volatile than the S&P 500 by 7.353%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.32%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $640M, which are smaller than Option Care Health quarterly revenues of $1.3B. Chemed's net income of $90.3M is higher than Option Care Health's net income of $60.1M. Notably, Chemed's price-to-earnings ratio is 29.80x while Option Care Health's PE ratio is 25.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.71x versus 1.09x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 14.11% compared to Chemed's net margin of -0.24%. Chemed's return on equity of 25.8% beat OptimizeRx's return on equity of -16.71%.

Chemed has a consensus price target of $675.00, signalling upside risk potential of 13.75%. On the other hand OptimizeRx has an analysts' consensus of $10.33 which suggests that it could grow by 27.1%. Given that OptimizeRx has higher upside potential than Chemed, analysts believe OptimizeRx is more attractive than Chemed.

Chemed has a beta of 0.494, which suggesting that the stock is 50.626% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.179, suggesting its more volatile than the S&P 500 by 17.909%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.32%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $640M, which are larger than OptimizeRx quarterly revenues of $32.3M. Chemed's net income of $90.3M is higher than OptimizeRx's net income of -$78K. Notably, Chemed's price-to-earnings ratio is 29.80x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.71x versus 1.61x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.